Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Heena Soni *Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Sandeep Tyagi *Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Kishor ManeDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA.
Anil M ShelkeDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA.
Pradeep KumarDivision of Infectious Disease, Department of Medicine and the Ruy V. Lourenco Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA.
Firat KayaCenter for Discovery & Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
David AllandDivision of Infectious Disease, Department of Medicine and the Ruy V. Lourenco Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA.ORCID 0000-0001-5196-1571
Matthew ZimmermanCenter for Discovery & Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Joel S FreundlichDepartment of Pharmacology, Physiology, and Neuroscience, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA.ORCID 0000-0002-3411-3455
Eric L NuermbergerCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0003-1440-9889
Funding
A Preclinical Program for Targeting Mycobacterium tuberculosis KasAR01AI153145 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI FREUNDLICH, JOEL STEPHEN · 2021 to 2024
$3.2M
HHS | NIH | All of Us Research Program (All of Us NIH) R01 AI-153145NIAID NIH HHS R01 AI153145
6 · The paper itself
Abstract
JSF-3285 is a promising preclinical candidate for tuberculosis that potently targets the
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The KasA inhibitor JSF-3285 improves the sterilizing activity of bedaquiline-pretomanid-containing regimens in a mouse model of tuberculosis. · full record | OpenQuestion